The German Biotech Manufacturing Bond provides financing for the construction and commissioning of a new pharmaceutical and biotechnology production facility located in Germany. The proceeds from this bond issue will be used to develop a modern manufacturing complex equipped with high-precision processing systems, cleanroom laboratories, and advanced automation technologies designed for pharmaceutical and life-science production.
The project aims to strengthen domestic manufacturing capacity within the European Union, addressing the growing demand for locally produced pharmaceutical components and biologics. The facility is designed to meet European GMP standards and will integrate state-of-the-art energy-efficient systems to ensure a sustainable long-term operation. Once completed, the plant will be capable of serving both contract manufacturing requirements and proprietary product development initiatives.
The bonds are issued as unsecured corporate debt instruments, representing a straightforward and transparent form of financing. There is no collateral or asset-based guarantee associated with the issue; repayment and coupon obligations are based solely on the issuer’s financial performance and operational capacity. The proceeds will be fully allocated toward capital expenditure, technological installations, and the initial operational setup of the facility.
This issuance forms part of a broader strategy to expand Europe’s pharmaceutical production independence and to enhance the region’s resilience against global supply-chain disruptions. The project also contributes to regional economic growth through job creation and the development of high-skilled employment in the fields of biotechnology, chemistry, and industrial automation.
The bond is denominated in euros and offers a fixed annual coupon, distributed on a quarterly basis. It is designed exclusively for professional and institutional investors who seek exposure to the industrial and healthcare manufacturing sectors through a stable, medium-term fixed-income allocation.
Subscription is available exclusively to professional and institutional investors within the European Union.
